Stockreport

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

ImmunityBio, Inc.  (IBRX) 
PDF  Company to Provide Regulatory, Sales, and Platform Updates at Investor Day including:In Q1, the company submitted a supplemental Biologics License Application (sBLA) fo [Read more]